Robust IP Portfolio Across Senescence Science & Regenerative Medicine

Immorta Bio commands a powerful and expanding patent estate that secures every strategic layer of our platform—from personalized stem cell therapies and senescence-targeting immunotherapies to exosome-based rejuvenation and organ regeneration.

Extensive IP Coverage

With 23 priority patents filed since 2022, our IP protects proprietary technologies behind our first in class senescence immunotherapy, SenoVax™ , our personalized stem cell regeneration platform, StemCellRevivify™ and cutting-edge exosome and progenitor cell innovations. This broad coverage spans therapeutic domains including:
‍
- Autoimmunity·
- Cancer microenvironment modulation
- Organ and liver failure· Heart regeneration
- Senescent cell clearance
-Immune rejuvenation
-NK cell and T cell-based immunotherapy

Our IP covers development, manufacturing, and clinical application, giving Immorta Bio a unique leadership position at the frontier of regenerative and longevity medicine.